Communiqués BioDelivery Sciences International, Inc.

Actions

BDSI

US09060J1060

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioDelivery Sciences International : Termination of a Material Definitive Agreement - Form 8-K	23/03/22	PU
BIODELIVERY SCIENCES INTERNATIONAL INC : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22/03/22	AQ
Collegium Completes the Acquisition of BDSI	22/03/22	AQ
BIODELIVERY SCIENCES INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	09/03/22	AQ
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine	24/02/22	AQ
BioDelivery Sciences International : Material Definitive Agreement - Form 8-K/A	15/02/22	PU
BIODELIVERY SCIENCES INTERNATIONAL INC Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)	15/02/22	AQ
Bam Bam Resources (NPEZF) could be well positioned to take advantage of the World Copper shortage	15/02/22	AQ
BioDelivery Sciences International : Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40 - Form 8-K	14/02/22	PU
BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences International to Collegium Pharmaceutical	14/02/22	AQ
BIODELIVERY SCIENCES INTERNATIONAL INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	14/02/22	AQ
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal	14/02/22	AQ
BioDelivery Sciences International : BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million - Form 8-K	20/01/22	PU
BIODELIVERY SCIENCES INTERNATIONAL INC : Results of Operations and Financial Condition (form 8-K)	20/01/22	AQ
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance	20/01/22	AQ
BIODELIVERY SCIENCES INTERNATIONAL INC : Regulation FD Disclosure, Other Events (form 8-K)	21/12/21	AQ
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032	20/12/21	GL
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032	20/12/21	GL
BIODELIVERY SCIENCES INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	03/11/21	AQ
BioDelivery Sciences Reports Solid Third Quarter 2021 Results - Form 8-K	03/11/21	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BioDelivery Sciences International, Inc.

Actions

BDSI

US09060J1060

Communiqués

Filtres